glp-1/glp-2 dual agonist and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Differential Responses of the GLP-1
Description
Clinical trials stop after a few years, and some of the currently FDA-approved drugs have only been around for a couple of years
The use of prazosin, an 1-adrenergic receptor blocker, showed that the ability of GLP-1RAs to reduce TNF- in plasma was disrupted, signifying the vital role of 1-adrenergic receptors in the anti-inflammatory action of GLP-1RAs
The dose-response analysis determined an ED of 242.9 mg/kg and a maximum efficacy (E max ) of 54%, based on 1-h post-administration values [71]
Gold PW, Goodwin FK, Chrousos GP
This review explores GLP-1's physiological functions, therapeutic potential, and intricate molecular mechanisms
Structure of the glucagon receptor in complex with a glucagon analogue
